Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ: BNTX )

100.31 +1.92 (+1.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,549,507
Open 100.13
Bid (Size) 98.46 (1)
Ask (Size) 100.00 (1)
Prev. Close 98.39
Today's Range 97.82 - 101.08
52wk Range 76.53 - 131.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
4 Analysts Have This To Say About BioNTech
Via Benzinga
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic
For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros. 
Via Stocktwits

Performance

YTD
-13.00%
-13.00%
1 Month
-12.98%
-12.98%
3 Month
-15.95%
-15.95%
6 Month
+1.05%
+1.05%
1 Year
+4.72%
+4.72%

More News

Read More
BioNTech Se (BNTX) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Peering Into BioNTech's Recent Short Interest
Via Benzinga
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
Via Benzinga
Exposures COVID-19
BioNTech Surpasses Q4 Revenue Estimates
Via The Motley Fool
US Stocks Likely To Open Lower After Trump Hints At Looming Recession: Expert Says Can't Rule Out A Bear Market As Indices Inch Towards Correction Territory
Via Benzinga
Topics Government
Exposures Political
BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Earnings Scheduled For March 10, 2025
Via Benzinga
Dow Gains Over 200 Points But Records Weekly Loss: Fear Among Investors Eases But Greed Index Remains In 'Extreme Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
BioNTech, Oracle And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Nasdaq Falls Into Correction As Tariffs Roil Wall Street: What's Moving Markets Friday?
Via Benzinga
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
BioNTech Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
FDA Places Clinical Hold On BioNTech's Early-Phase Trial For RNA-Based Malaria Vaccine
Via Benzinga
Exposures Product Safety
BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
From BioNTech SE
Via GlobeNewswire
Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.
Via Investor's Business Daily
Pfizer Edges Higher As Covid Sales Decline, But Still Beat Expectations
Via Investor's Business Daily
Exposures COVID-19
BioNTech Completes Acquisition of Biotheus
From BioNTech SE
Via GlobeNewswire
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
Via Investor's Business Daily
Exposures COVID-19
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
Via The Motley Fool
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Via Benzinga
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Via Investor's Business Daily
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.